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Abstract
Background: Patients with early colorectal cancer (stages I–II) generally have a good prognosis, but a subgroup of
15–20% experiences relapse and eventually die of disease. Occult metastases have been suggested as a marker for
increased risk of recurrence in patients with node-negative disease. Using a previously identified, highly accurate
epigenetic biomarker panel for early detection of colorectal tumors, we aimed at evaluating the prognostic value of
occult metastases in sentinel lymph nodes of colon cancer patients.
Results: The biomarker panel was analyzed by quantitative methylation-specific PCR in primary tumors and 783
sentinel lymph nodes from 201 patients. The panel status in sentinel lymph nodes showed a strong association
with lymph node stage (P = 8.2E−17). Compared with routine lymph node diagnostics, the biomarker panel had a
sensitivity of 79% (31/39). Interestingly, among 162 patients with negative lymph nodes from routine diagnostics,
13 (8%) were positive for the biomarker panel. Colon cancer patients with high sentinel lymph node methylation
had an inferior prognosis (5-year overall survival P = 3.0E−4; time to recurrence P = 3.1E−4), although not significant.
The same trend was observed in multivariate analyses (P = 1.4E−1 and P = 6.7E−2, respectively). Occult sentinel lymph
node metastases were not detected in early stage (I–II) colon cancer patients who experienced relapse.
Conclusions: Colon cancer patients with high sentinel lymph node methylation of the analyzed epigenetic biomarker
panel had an inferior prognosis, although not significant in multivariate analyses. Occult metastases in TNM stage II
patients that experienced relapse were not detected.
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Background
Colorectal cancer is a frequent disease, ranking third
among the most common cancers in men and second in
women. The mortality is high, with an estimated number
of cancer deaths approaching 700,000 per year,
worldwide [1]. Histopathological tumor staging by the
tumor-node-metastasis (TNM) system remains the best
prognostic marker for colorectal cancer, with lymph
node status as the strongest prognostic factor. Currently,
lymph node status is used for clinical decision-making
regarding adjuvant chemotherapy [2]. Despite this, stage
alone has clear limitations in terms of treatment stratifi-
cation, resulting in both under- and over-treatment of
patients [3, 4].
Colon cancer patients with TNM stage III are
routinely offered postoperative fluoropyrimidine-based
chemotherapy, which decreases the risk of death by
10–15% compared to surgery alone [2]. In contrast,
no statistically significant survival benefit has been
found for adjuvant chemotherapy in patients with
stage II disease. Except for patients with accepted
clinical high risk features, such as a low number of
lymph nodes examined, tumor perforation, T4 lesions,
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or lack of clean resection margins, stage II patients
are not routinely offered adjuvant chemotherapy [5].
However, approximately 15–20% of patients with
stage II disease will experience relapse [6]. Thus, oc-
cult metastases in lymph node-negative patients have been
suggested as a potential marker for the systemic spread of
tumor cells [4, 7, 8]. Consequently, correct identification
of the stage II patients that are at risk of recurrence and
potentially would benefit from adjuvant chemotherapy
would be highly valuable in a clinical perspective.
Epigenetic aberrations, including promoter DNA
hypermethylation, is frequently seen during colorectal
cancer development [9, 10], and several such bio-
markers have been suggested for the early detection
of this disease. High accuracy is important and best
achieved by a panel of individually well-performing
biomarkers compared to any single marker alone [11].
Previously, we have identified a highly sensitive and
specific panel of DNA methylation biomarkers for
colorectal tumors [12–14]. The aim of the present
study was twofold: (A) to evaluate the prognostic
value of this biomarker panel in ex vivo-sampled
sentinel lymph nodes from colon cancer patients and
(B) to investigate whether the markers can identify
early stage (I–II) patients at high risk of relapse, by
identifying occult metastases in histologically negative
sentinel lymph nodes.
Results
DNA methylation biomarker panel status of colon cancers
Among the 197 colon cancer patients who had pri-
mary tumor biopsies available for analysis, 193 (98%)
were positive for the DNA methylation biomarker
panel. The cancer biomarker panel status was associ-
ated with neither microsatellite instability (MSI) status
nor BRAF mutation status, although all cancers nega-
tive for the biomarker panel (n = 4) were MSS and
had no BRAF V600E hotspot mutation.
DNA methylation biomarker panel status of lymph nodes
Normal lymph nodes
The 43 normal lymph nodes collected from patients
with benign bowel disease had generally low levels of
DNA promoter methylation (one could not be deter-
mined). The mean percent methylated reference
(PMR) value across the biomarker panel in the test
series of normal lymph nodes was 0.23, range 0 to
0.64. The threshold for scoring samples as biomarker
panel positive was set to the closest upper integer
across the test series, PMR ≥ 1. The validation series
had a mean PMR value in the same range as the test
series (mean 0.10, range 0 to 0.45). All normal lymph
node controls were negative for the DNA methylation
biomarker panel (Fig. 1).
Lymph nodes from cancer patients
Among the 782 successfully analyzed sentinel lymph
nodes from colon cancer patients (one sentinel lymph
node could not be determined), 92 (12%) were positive
for the DNA methylation biomarker panel. There was
no statistically significant difference in the methylation
frequency between the test and validation series. In sub-
sequent statistical analyses, the two series were pooled
for robustness. Across the series, there was a strong as-
sociation with hematoxylin-erythrosin-safranin (HES)
staining: 43/54 (80%) of the HES-positive lymph nodes
were positive for the DNA methylation biomarkers
(P = 1.3E−34; Fisher’s exact). In addition, 49 (7%) of the
726 HES-negative samples were methylation-positive
(P = 1.3E−34; Additional file 1: Figure S1a). The average
PMR values across the DNA methylation biomarker
panel for the individual lymph nodes are visualized in
Fig. 1. Based on receiver operating characteristics (ROC)
curve analysis, the average PMR values per lymph node,
across the DNA methylation biomarker panel, could
separate HES-positive from HES-negative patient lymph
nodes with an area under the ROC curve (AUC) of
0.914 (asymptotic significance 2.9E−24; Fig. 2).
DNA methylation biomarker panel status of lymph nodes
at the patient level
Based on the test series of normal lymph node controls,
patients with a methylation index ≥ 1 were considered
lymph node methylation-positive, whereas patients with
a methylation index < 1 were considered to have an
unmethylated lymph node status. Among 201 patients
with colon cancer, 44 (22%) were positive for the DNA
methylation biomarker panel in the analyzed lymph
Fig. 1 Average DNA methylation across the biomarker panel for
individual lymph nodes. Controls: mean 0.18; 95% CI [0.13–0.23]. HES
negative: mean 0.52; 95% CI [0.40–0.64]. HES positive: mean 10.73; 95%
[CI 7.84–13.62]. The red line indicates the scoring threshold (1.0).
Abbreviations: CI confidence interval, HES hematoxylin-erythrosin-
safranin, PMR percentage methylated reference (methylation value)
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nodes. The distribution of HES-positive patients and
methylation biomarkers was similar to the distribution
seen for individual lymph nodes: 31/39 (79%) of the pa-
tients with one or more HES-positive lymph node(s) an-
alyzed were also biomarker panel positive. Interestingly,
13 (8%) of the 162 patients with only HES-negative
lymph nodes were methylation-positive (Additional file 1:
Figure S1B). Furthermore, patients in which one or more
of the analyzed lymph nodes were HES-positive had sig-
nificantly higher lymph node methylation index (mean
5.24, 95% CI [3.80–6.67]) than did patients with HES-
negative lymph nodes (mean 0.45, 95% CI [0.34–0.57],
P < 1E−4, Mann-Whitney U; Fig. 3). Finally, based on
ROC curve analysis, the methylation index could distin-
guish colon cancer patients with positive HES from
patients with negative HES with a resulting AUC value
of 0.895 (asymptotic significance 1.9E−14). There was
no association between the methylation index and the
number of lymph nodes analyzed per patient (Kruskal-
Wallis). However, a statistically significant association
between a positive lymph node biomarker panel status
and the lymph node stage was observed. Of the 139
pN0 patients, only 10 (7%) were biomarker panel posi-
tive, whereas 20 out of the 47 (43%) pN1 patients and
as much as 14 out of the 15 (93%) pN2 patients were
biomarker panel positive (P = 8.2E−17, Pearson’s chi-
square). A significant association was seen between the
biomarker panel status in lymph nodes from cancer pa-
tients and the TNM stage, whereas 2/38 (5%) and 8/101
(8%) of the patients with local disease (stages I and II,
respectively) were biomarker positive and as much as
34/62 (55%) of the patients with regional disease (stage
III) were positive (P = 4.1E−13; Pearson’s chi-square).
Prognostic relevance of the methylation biomarker panel
Within a median 5.0-year follow-up (max 9.8 years),
there were 58 (29%) deaths, including 26 (13%) disease-
specific deaths among the 201 patients included in the
study. Thirty-two (16%) experienced relapse (distant me-
tastases and/or locoregional relapses). Distant metastases
were found in 29 (91%) of these.
Among patients that were positive for the DNA
methylation biomarker panel in the analyzed lymph
nodes (22%; 44 out of 201), 15/44 (34%) experienced
relapse or died from colorectal cancer. In contrast, only
17/157 (11%) of patients that were negative for the DNA
methylation biomarker panel experienced relapse or died
from the disease (P = 1.9E−4; Pearson’s chi-square). This
comparison included all patients and also stage III
patients with HES-positive lymph nodes. Among the 139
lymph node-negative patients, 11 (8%) experienced dis-
ease relapse. These patients were also negative for the
DNA methylation biomarker panel. In addition to this
dichotomous comparison, the methylation index as a
continuous variable, as well as the methylation level of
individual genes in the biomarker panel, was compared
between pN0 patients with and without relapse. No
associations were found (Mann-Whitney U), underscor-
ing that the detected methylation of sentinel lymph
nodes was not suitable to differentiate between pN0
patients with and without relapse.
Based on the association between the biomarker panel
status in lymph nodes from cancer patients and the
TNM stage, it was not surprising that patients with
methylation-positive lymph nodes had an inferior 5-year
Fig. 2 Receiver operating characteristics curve of the ability of the
biomarker panel to separate HES-positive from HES-negative lymph nodes
from colon cancer patients. Abbreviations: AUC area under the receiver
operating characteristics curve, HES hematoxylin-erythrosin-safranin
Fig. 3 Methylation index across the lymph nodes from colon cancer
patients. HES-positives include patients for whom one or more of the
lymph nodes subjected to methylation analysis were HES-positive.
Abbreviation: HES, hematoxylin-erythrosin-safranin
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overall survival (50% events) compared with patients
with methylation-negative lymph nodes (23% events;
P = 3.0E−4, Wald test; Fig. 4a) in univariate analysis.
The lymph node methylation-positive patients also expe-
rienced more frequent recurrence (34%) after 5 years
follow-up than did those with negative lymph nodes
(11%; P = 3.1E−4, Wald test; Fig. 4b).
When stratified according to stage, the same trends of
inferior overall 5-year survival and more recurrences
could be seen for stage III patients with methylation-
positive lymph nodes, although this was not statistically
significant (P = 1.4E−1 and P = 6.7E−2, respectively;
Wald test; Fig. 4c, d). Survival analyses were not
performed for early stage (I and II) patients, due to a
limited number of methylation index-positive cases. Of
importance, the distribution of the number of sentinel
lymph nodes analyzed was equal among recurring and
non-recurring patients, also when stratified according to
stage (Mann-Whitney U test, P = 9.6E−1).
By using a stepwise selection procedure by Akaike
information criterion (AIC), patient age and stage were
identified as relevant predictor variables for stage III pa-
tients. From multivariate Cox regression, including these
additional covariates, a trend similar to the univariate
analysis could be seen for the prognostic value of the
methylation index (overall survival, P = 1.3E−1; time to
recurrence, P = 8.4E−2).
Discussion
Due to the high accuracy of the present DNA methyla-
tion biomarker panel for detecting malignant as well as
benign colorectal tumors [13, 14], we aimed at investi-
gating whether the panel could improve current lymph
node diagnostics by detecting methylation in HES-
negative lymph nodes from patients that later experi-
enced relapse. To evaluate this, we analyzed the primary
tumor in addition to a median of four sentinel lymph
nodes from ~200 colon cancer patients, amounting to
Fig. 4 Methylated lymph nodes are associated with poor patient outcome. a–d Survival analyses for methylation status of colon cancer patients’
lymph nodes. Blue curves represent an unmethylated lymph node status whereas green curves represent a methylated lymph node status in colon
cancer patients. a, c Overall survival analysis. b, d Time to recurrence analysis. The plots have been generated using the Kaplan-Meyer method, and P
values were calculated by the Wald test
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more than 1000 clinical samples. Indeed, compared to
the number of lymph nodes that were histologically
positive, a significantly higher number was methylation-
positive, opening up the possibility that the methylation
biomarkers could be more sensitive than HES staining
alone in detecting small metastases. However, all 11 pN0
relapsing patients in the dataset were also lymph node
methylation-negative, and we were not able to identify
the colon cancer patients that experienced relapse.
The aim of the sentinel node approach is to enable a
more thorough analysis of those lymph nodes that are
expected to have the highest risk of metastatic disease
[7]. However, an extensive meta-analysis has demon-
strated that the sentinel lymph node procedure has a
low sensitivity for lymph node metastasis detection [15].
In a previous report analyzing the same clinical material
used in the present study, detection of occult sentinel
lymph node metastases by Cytokeratin 20 and Mucin 2
mRNA quantification had no prognostic value [16]. It
cannot be ruled out that the low sensitivity of the senti-
nel lymph node procedure might have impacted the re-
sults of both studies. Interestingly, molecular tumor cell
detection in regional lymph nodes, not restricted to sen-
tinel lymph nodes, has been associated with poor overall
and disease-free survival in meta-analyses [8]. Further-
more, in a recent prospective multicenter trial, a high
molecularly determined micrometastasis volume in
lymph nodes was shown to be an independent prog-
nostic factor for poor overall and disease-free survival
[17]. Thus, the lack of prognostic value for pN0
patients in the present study may be related to the
fact that the DNA methylation analyses were
restricted to the sentinel lymph nodes and not all
available regional nodes.
The methylation level of patient’s lymph nodes was
evaluated using a methylation index, comprising the
average PMR value across six genes and across all lymph
nodes analyzed from a patient. This way, the methyla-
tion index was not affected by the number of lymph
nodes analyzed per patient (ranging from 1 to 10). To
exclude that a single methylation-positive lymph node
was potentially “masked” in the methylation index by
the presence of several methylation-negative lymph
nodes, all analyzed lymph nodes among all pN0
patients that experienced relapse were analyzed indi-
vidually and confirmed to be negative. Although we
could not detect occult metastases in the relapsing
pN0 patients, survival analyses revealed a prognostic
effect of the DNA methylation biomarkers in the
overall cohort, which was highly significant in univari-
ate analyses. The results were not statistically signifi-
cant in multivariate analyses, but the clear trend
indicated that significance could be achievable in a
larger patient series.
Thirteen of the patients had methylation-positive
sentinel lymph nodes that were negative by HES
staining. Interestingly, at the patient level, three (23%)
of these patients had a positive lymph node metasta-
sis status (pN1 or pN2)—based on evaluation of other
lymph nodes than those included for molecular ana-
lyses in the present study. This indicated that the
methylation-positive lymph nodes might harbor me-
tastases overlooked during the pathological evaluation
or that the metastases were restricted to the half of
the nodes that were subjected to methylation analysis.
In such a context, the biomarker panel could be of
added value in lymph node diagnostics.
For the analyses, we have used real-time quantitative
methylation-specific PCR (qMSP; also called Methy-
Light) [18]. This is a streamlined and common method
for methylation analyses, which can be easily standard-
ized for large sample series [19]. Although the method is
estimated to be able to detect 1 methylated allele among
10,000 unmethylated [18], it may not be sensitive
enough for detecting potentially rare methylation events
in lymph nodes that are negative in histological analyses.
In these reactions, the rare methylated templates might
be outcompeted by the highly abundant unmethylated
DNA, possibly providing false negative results. An inter-
esting alternative could be droplet digital PCR, where
the amplification step is partitioned into thousands of
droplets with individual PCRs. Using such sample dilu-
tion, the competition is significantly reduced, increasing
the chances of detecting rare alleles [20]. Indeed,
detection limits down to 0.001% have been reported
[21]. Digital PCR is commonly used for copy number
variation analysis and mutation/rare variant detection
[22] but has recently been used as an alternative to real-
time quantitative methylation-specific PCR [23–25].
Conclusions
In summary, we have demonstrated that the epigen-
etic biomarker panel analyzed here by real-time
methylation-specific PCR showed a strong association
with both HES staining and lymph node stage. Colon
cancer patients with high sentinel lymph node methy-
lation had an inferior prognosis, although not signifi-
cant in multivariate analyses. Occult metastases in




The present study comprised 1023 DNA samples from
201 colon cancer patients and 21 controls, consecutively
collected at Stavanger University Hospital in the period
of 2003 until 2010 [16, 26]. Clinical and genetic charac-
teristics of the patients are listed in Table 1.
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Sentinel lymph node sampling
Ex vivo sentinel lymph node mapping was performed as
previously described [26]. The lymph nodes were divided
in two. One part was formalin fixed and subjected to
staining with hematoxylin-erythrosin-safranin (HES) for
routine histological evaluation [27]. The second part was
snap-frozen in liquid nitrogen and stored at −80 °C for
molecular analyses [26].
Test and validation series
From the colon cancer patients, 197 primary tumors and
783 sentinel lymph nodes were available for molecular
analyses (median 4 lymph nodes per patient; range 1 to
10). Control samples included 43 normal lymph nodes
from 21 patients (median 2 lymph nodes per patient;
range 1 to 4) with benign disease undergoing bowel
resection. The clinical material was divided into a test
and validation series. The test series was randomly
selected from the consecutive series and comprised 77
colon cancer patients, including 75 primary carcinomas,
292 patient lymph nodes, and 26 normal lymph node
controls. The remaining validation series counted 124
patients and included 122 primary carcinomas, 491 pa-
tient lymph nodes, and 17 normal lymph node controls.
The test series was used to set thresholds for methyla-
tion scoring. In subsequent statistical analyses, the two
series were pooled for robustness.
DNA isolation and promoter methylation analyses
DNA from tumor samples and lymph nodes was
extracted using the DNeasy Mini Kit (Qiagen; first 129
patients) or the Allprep RNA/DNA kit (Qiagen), as pre-
viously described [16]. For each sample, 1.3 μg DNA was
bisulfite treated using the EpiTec Bisulfite kit (Qiagen).
DNA desulfonation and purification was performed
automatically, using a QiaCube (Qiagen), and the DNA
was eluted in 40 μl elution buffer. The promoter methy-
lation status of the six genes CNRIP1, FBN1, INA, MAL,
SNCA, and SPG20 comprising the biomarker panel was
analyzed individually by quantitative methylation-
specific PCR (qMSP) as previously described [13, 14].
Briefly, samples were analyzed in triplicates in 384 well
plates generated by a pipetting robot (EpMotion 5075,
Eppendorf ). The reaction volume in each well was 20 μl
comprising 30 ng bisulfite-treated DNA, 0.9 μM each of
the forward and the reverse primer, 0.2 μM 6-FAM
labeled probe [14] with a minor groove binder non-
fluorescent quencher, and 1× TaqMan Universal PCR
master mix NoAmpErase UNG (Life Technologies). A
standard curve was generated using a 1:5 serial dilution
(32.5–0.052 ng) of commercially in vitro methylated
DNA (IVD; CpGenome Universal Methylated DNA;
Millipore) and was used to determine the quantity from
the resulting quantification cycle (Cq) values. For all
samples, Cq values above 35 were censored, according
to the recommendations from the manufacturer (Life
Technologies). The standard curve was included in each
384 well plate along with a methylated control (IVD), an
unmethylated control (normal blood), and a negative
control (water). For normalization of possible variation
in bisulfite-treated DNA input, the ALU-C4 repeat was
used [28]. All 384 well plates were amplified using the
7900HT Sequence Detection System (TaqMan; Life
Technologies); 95 °C for 10 min, then 45 cycles of 95 °C
for 15 s followed by 60 °C for 1 min. For each sample,
the median quantity of the triplicates was used to

























< 70 60 30










Wild type 144 73
The MSS group includes both MSS and MSI-low samples. BRAF status is evaluated
for the V600E hotspot. For one cancer, BRAF status could not be determined
MSI microsattelite instability, MSS microsattelite stable
Lind et al. Clinical Epigenetics  (2017) 9:97 Page 6 of 8
calculate the percentage of methylated molecules per
sample (PMR value) [19] by normalizing the marker-
specific quantity to the ALU-C4 repeat value, relative to
the same ratio for the fully methylated control (IVD).
Definition of biomarker positivity
Colon cancers were considered DNA methylation
biomarker panel positive when a minimum of two of
the six biomarkers analyzed had a PMR value ≥ 7, as
previously described [14]. For individual lymph nodes,
the mean PMR value across the biomarker panel was
calculated. At the patient level, the lymph node
methylation status was determined by calculating a
methylation index: the average PMR value across all
genes in the biomarker panel and across all lymph
nodes analyzed from the patient in question. To
dichotomize the results, for individual lymph nodes
and per patient, into methylated and unmethylated
groups, scoring thresholds were determined from the
test series (see the “Results” section).
Statistical analyses
Analyses were performed with the IBM SPSS statistics
21 software (IBM, New York, USA) and R 3.2.2 using
the “survival” package [29]. Pearson’s chi-square and
Fisher’s exact tests were run to evaluate independence
between categorical variables. ROC curves were used
to assess the accuracy of the methylation status to
differentiate between (1) lymph nodes with negative
or positive HES status and (2) patients with negative
or positive HES lymph node staining, restricted to the
lymph nodes analyzed for methylation. The accuracy
is expressed as the area under the ROC curve (AUC).
The state variable was HES positivity. Potential differ-
ences in the methylation index were further evaluated
by the Kruskal-Wallis and Mann-Whitney U tests. P
values were derived from two-sided tests using a sig-
nificance level of 0.05.
For survival analyses, the Kaplan-Meier method was
used to generate survival plots. In agreement with
previously presented guidelines [30], overall survival
was defined as the time from surgery to death of any
cause. Time to recurrence was accordingly defined as
the time from surgery to the first event of either
death from the same cancer, locoregional recurrence,
or distant metastases [30]. The survival curves were
generated using dichotomized methylation values and
P values derived from a Wald test. To evaluate
whether lymph node methylation had significant inde-
pendent impact on patient survival, multivariate Cox
regression was used. Relevant predictor variables for
the Cox regression model were identified by using a
stepwise selection procedure by Akaike information
criterion (AIC) [31].
Additional file
Additional file 1: Figure S1. Venn diagram illustrating the overlap
between HES-positive and DNA methylation biomarker-positive lymph
nodes. (A) Individual lymph node level. (B) Patient level. Abbreviation:
HES, hematoxylin-erythrosin-safranin. (PDF 146 kb)
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